Ribonucleotide reductase, the rate-limiting enzyme for de novo DNA synthesis, is a common target for chemotherapy. Its increased activity in cancer cells is associated with malignant transformation and proliferation. Trimidox is a specific ribonucleotide reductase inhibitor that reduces levels of dGTP and dCTP in HL-60 cells, inducing apoptosis via activation of caspases without altering the cell cycle distribution. Trimidox inhibits growth of human promyelocytic leukemia HL-60 cells with an IC50 value of 35 μM.
[1] szekeres t, fritzer m, strobl h, et al. synergistic growth inhibitory and differentiating effects of trimidox and tiazofurin in human promyelocytic leukemia hl-60 cells[j]. blood, 1994, 84(12): 4316-4321.
[2] elledge s j, zhou z, allen j b. ribonucleotide reductase: regulation, regulation, regulation[j]. trends in biochemical sciences, 1992, 17(3): 119-123.
